share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/11/28 05:14

Moomoo AI 已提取核心訊息

Titan Pharmaceuticals received two notices from Nasdaq regarding listing compliance issues. On November 22, 2024, the company was notified of non-compliance with Rule 5250 for failing to file its Q3 2024 Form 10-Q timely. The company has until January 21, 2025, to submit a compliance plan, with a possible extension until May 19, 2025, if Nasdaq accepts the plan.On November 25, 2024, Nasdaq issued a second notice citing non-compliance with Rule 5605 regarding audit committee requirements, following Brynner Chiam's appointment as Acting Principal Executive Officer and Acting Principal Financial Officer. The company has until November 6, 2025, or May 5, 2025 (if the annual meeting is held before May 5, 2025) to regain compliance.Additionally, WithumSmith+Brown resigned as the company's independent auditor on November 22, 2024, following the departure of former CEO Dato' Seow Gim Shen. The company is currently seeking a new auditor, with Withum confirming no disagreements or reportable events during their tenure through September 30, 2024.
Titan Pharmaceuticals received two notices from Nasdaq regarding listing compliance issues. On November 22, 2024, the company was notified of non-compliance with Rule 5250 for failing to file its Q3 2024 Form 10-Q timely. The company has until January 21, 2025, to submit a compliance plan, with a possible extension until May 19, 2025, if Nasdaq accepts the plan.On November 25, 2024, Nasdaq issued a second notice citing non-compliance with Rule 5605 regarding audit committee requirements, following Brynner Chiam's appointment as Acting Principal Executive Officer and Acting Principal Financial Officer. The company has until November 6, 2025, or May 5, 2025 (if the annual meeting is held before May 5, 2025) to regain compliance.Additionally, WithumSmith+Brown resigned as the company's independent auditor on November 22, 2024, following the departure of former CEO Dato' Seow Gim Shen. The company is currently seeking a new auditor, with Withum confirming no disagreements or reportable events during their tenure through September 30, 2024.
泰坦製藥收到納斯達克關於上市合規問題的兩次通知。2024年11月22日,公司被告知因未及時提交2024年第三季度10-Q表格而違反了第5250條規則。公司必須在2025年1月21日之前提交合規計劃,如果納斯達克接受該計劃,則可能延長至2025年5月19日。2024年11月25日,納斯達克發佈了第二次通知,指出公司在審計委員會要求方面違反了第5605條規則,這表現在Brynner Chiam被任命爲代理首席執行官和代理財務長之後。公司必須在2025年11月6日之前,或2025年5月5日之前(如果年度會議在2025年5月5日之前舉行)恢復合規。此外,WithumSmith+Brown在2024年11月22日因前首席執行官Dato' Seow Gim Shen的離職而辭去公司獨立核數師職務。公司目前正在尋找新的核數師,Withum確認在他們任期內截至2024年9月30日沒有任何分歧或可報告事件。
泰坦製藥收到納斯達克關於上市合規問題的兩次通知。2024年11月22日,公司被告知因未及時提交2024年第三季度10-Q表格而違反了第5250條規則。公司必須在2025年1月21日之前提交合規計劃,如果納斯達克接受該計劃,則可能延長至2025年5月19日。2024年11月25日,納斯達克發佈了第二次通知,指出公司在審計委員會要求方面違反了第5605條規則,這表現在Brynner Chiam被任命爲代理首席執行官和代理財務長之後。公司必須在2025年11月6日之前,或2025年5月5日之前(如果年度會議在2025年5月5日之前舉行)恢復合規。此外,WithumSmith+Brown在2024年11月22日因前首席執行官Dato' Seow Gim Shen的離職而辭去公司獨立核數師職務。公司目前正在尋找新的核數師,Withum確認在他們任期內截至2024年9月30日沒有任何分歧或可報告事件。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息